Evidence map›Paper›PMID 37184781›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

LncRNA OTUD6B-AS1 overexpression promoted GPX4-mediated ferroptosis to suppress radioresistance in colorectal cancer.

Zilang Zhang, Baolong Ye, Yiban Lin, Wenjun Liu, Jianzhong Deng, Wu Ji

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Ferroptosis: the balance between death and survival in colorectal cancer.International journal of biological sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zilang ZhangDepartment of General Surgery, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, 305 Zhongshan East Road, Nanjing, 210002, Jiangsu, China.
Baolong YeDepartment of General Surgery, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, 305 Zhongshan East Road, Nanjing, 210002, Jiangsu, China.
Yiban LinDepartment of Anorectal Surgery, The First People's Hospital of Foshan, 81 Lingnan Avenue North, Foshan, 528000, Guangdong, China.
Wenjun LiuDepartment of General Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
Jianzhong DengDepartment of Anorectal Surgery, The First People's Hospital of Foshan, 81 Lingnan Avenue North, Foshan, 528000, Guangdong, China. 18038863613@163.com.
Wu JiDepartment of General Surgery, Jinling Hospital, the First School of Clinical Medicine, Southern Medical University, 305 Zhongshan East Road, Nanjing, 210002, Jiangsu, China. jiwu_med@163.com.ORCID http://orcid.org/0000-0001-8693-8427
Nanjing General Hospital of Nanjing Military Command · CNFirst People's Hospital of Foshan · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiotherapy is widely employed in colorectal cancer (CRC) treatment but is often compromised by developed radioresistance. This study explored the mechanism of long non-coding RNA ovarian tumor domain containing 6B-antisense RNA1 (lncRNA OTUD6B-AS1) in CRC radioresistance through tripartite motif 16 (TRIM16).

methodsCRC and non-cancerous tissues were collected and radioresistant CRC cells were established, with real-time quantitative polymerase chain reaction to determine gene expression in tissues and cells. Radioresistance was evaluated by cell counting kit-8 assay and immunofluorescence (γ-H2AX) and ferroptosis was tested by Western blot assay (ACSL4/GPX4) and assay kits (Fe

resultsLncRNA OTUD6B-AS1 and TRIM16 were poorly expressed (P < 0.01) in CRC tissues and cells and further decreased (P < 0.01) in radioresistant CRC cells. OTUD6B-AS1 overexpression decreased cell survival (P < 0.01), increased γ-H2AX levels (P < 0.01), and elevated ferroptosis and oxidative stress (P < 0.01) after X-ray radiation. Ferroptosis inhibitor attenuated radioresistance (P < 0.01) caused by lncRNA OTUD6B-AS1 overexpression. LncRNA OTUD6B-AS1 stabilized TRIM16 mRNA via binding to HuR. TRIM16 knockdown reduced ferroptosis and increased radioresistance (P < 0.05).

conclusionOTUD6B-AS1 overexpression stabilized TRIM16 via binding to HuR and increased GPX4-mediated ferroptosis, thus attenuating CRC radioresistance. Our study provided a new rationale for the treatment of CRC.

Indexed as

Colorectal NeoplasmsFerroptosisMicroRNAsRNA, Long NoncodingCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansTripartite Motif ProteinsUbiquitin-Protein LigasesMicroRNAsRNA, Long NoncodingTRIM16 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesColorectal cancerFerroptosisOTUD6B-AS1Radiation resistanceTRIM16

Identifiers

PMID37184781
OpenAlexW4376618308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.